Benefits in the event of a pandemic: NaturalVue® offers multiple solutions for patients and ophthalmologists
ATLANTA – (BUSINESS WIRE) – US-based medical device company and manufacturer of the NaturalVue® (etafilcon A) 1-Day Multifocal Contact Lenses (“ NaturalVue MF ”) Visioneering Technologies, Inc (ASX: VTI) (“Visioneering”, “VTI” or “the Company”) is pleased to provide an update on the impact of NaturalVue on the dynamics of practice and the lives of patients.
Since the inception of the company in 2008, VTI continues to make an indelible impact on the lives of patients ages 7 to 70 by providing contact lenses of unparalleled versatility. Together, the revolutionary NaturalVue Multifocal and NaturalVue® Sphere contact lenses redefine vision by treating myopia and hyperopia in adults, pediatric myopia, accommodation problems in young adults and the special needs of mature presbyopia.
The innovative NaturalVue® brand has proven to be a game changer for patients, as well as a sustainable source of business for Eye Care Professionals (ECPs) – even in the midst of a global pandemic. Dr. Ronald L. Hoffman, OD, optometrist at Huntington Station, New York, USA, can attest to the essential role of NaturalVue contact lenses. “Without a doubt, NaturalVue has helped maintain my practice during the most difficult times. I am able to maintain a thriving contact lens practice in today’s competitive market due to the unique properties of NaturalVue contact lenses and the loyalty of NaturalVue patients.
Giving 5 billion pediatric myopic people a chance
Pediatric myopia is the myopia of the child. Nearsighted children cannot see clearly at a distance, and their vision typically deteriorates with age, putting them at a life of high risk for blindness and other serious eye diseases. Up to 90% of children are nearsighted in some countries, and according to the Journal of the American Medical Association, house arrest during COVID-19 has caused an increase of up to 3X in the prevalence of myopia among young people children in 2020 compared to the previous 5. years. It is more important than ever to act urgently in the best interests of the youngest and most vulnerable patients. As a global leader in myopia management, VTI provides practitioners with a powerful tool to control the worsening of myopia over time, while simultaneously correcting distance vision. Recently published data over 5 years (59 months) of use in children show an exciting long-term reduction or inhibition of myopia progression in children wearing NaturalVue MF. Additionally, as a founding member of the Global Myopia Awareness Coalition (GMAC), VTI serves alongside the world’s largest eye care companies to continue to drive myopia management actions among PKUs and parents.
Nick Dash, MCOptom, of the Midland Eye Private Clinic in Birmingham, UK, was delighted to learn that of the 153 children studied, 93% experienced a slowdown in the progression of their myopia, and 65% experienced a slowing down greater than 70%.4 “These studies fully replicate the experience I have in my practice in the UK. Our patient audits (including myopia and axial eye length measurement) endorse our current strategy for managing childhood myopia, using NaturalVue Multifocal as one of my preferred interventions.
Dr Tom Aller of San Bruno, California, USA, and renowned expert in pediatric myopia, said: “The data from VTI in children to date are very encouraging and support the use of NaturalVue MF in the treatment of pediatric myopia. I am also delighted to see VTI launch its randomized clinical trials, as they continue to be at the forefront of rapidly evolving and expanding myopia research.
1.8 billion presbyopes need our help
Presbyopia is the age-related loss of near vision that affects almost everyone over the age of 45-50. With a growing presbyopic population around the world, more and more PCEs are focusing on this key demographic, who are already in their exam chairs. Almost 71% of patients presenting to clinics today are 37 years of age or older.2 While many current multifocal contact lenses perform less well for this large group, NaturalVue® multifocal contact lenses only allow practitioners to maintain – and develop – their practices with presbyopic patients.
With its Neurofocus Optics® technology and extended depth of field design, practitioners report that NaturalVue contact lenses breathe new life into the fit of presbyopes. Susan A. Resnick, OD FAAO, New York, USA, says, “Presbyopes grew up with contact lenses and have high expectations. With nearly twice the clear vision range compared to the best corrected eyeglass acuity,3 I now have a lens that gives me more opportunities to keep presbyopics in contact lenses and my practice.
The Young, the Aging, and the In-between: ECPs signal growing use of NaturalVue Multifocal
With the current increase in the use of digital devices, digital eye strain is experienced by patients of all ages, and NaturalVue MF contact lenses are increasingly used to treat digital eye strain. This expansion in the use of specialties is a high growth area for ECPs, especially as they offer more specialized services to their community. Stephanie Lyons, OD, of Lyons Family Eye Care in Chicago, Illinois, USA, says, “I attribute a lot of the growth we’ve seen to specialty services, including specialty contact lenses like NaturalVue, Care pediatric and vision therapy. All services specializing in optometry can be an important source of income and an avenue of distinction. ”
Young patients with near-work eye strain, also known as accommodative stress, and binocular problems can use bifocal glasses or glasses to reduce eye strain from near tasks, but ECPs have found that NaturalVue multifocal lenses can also reduce accommodative stress, with the benefits that come with contact lenses. Drs. Jennifer Dattolo and Amber Zaunbrecher presented a poster at a recent American Optometric Association meeting on the use of NaturalVue Multifocal contact lenses to help patients with accommodation disorders. “Their acuity improves over time,” explains Dr. Dattolo. “And NaturalVue MF allows for better vision in the periphery than they can get with glasses.”
Pandemic Pearls: Ultimate Pressure Test Proves Value of NaturalVue Multifocal
Retaining patients throughout the pandemic halt was a monumental challenge for most PKUs. COVID-19 has pushed more patients to shop online, with 36% of patients no longer purchasing contact lenses from their ECPs.4 Losing 200 patients could cost a practice approximately $ 54,000 in product revenue, plus sales of lost accessories and eyewear.6
Practices that used differentiated products, such as NaturalVue® Multifocal Contact Lenses, maintained a significant portion of their patients, even during the pandemic. In fact, at the height of the discontinuation, NaturalVue Multifocal contact lenses had a retention rate of 91%,7 with a repurchase rate of 92%,8 which compares favorably with published annual retention rates for certain other multifocal contact lenses.9
Redefining vision, life and the eye care industry
VTI is an innovative eye care company committed to redefining vision. Clinical results, financial results and the growing use of NaturalVue® products for a variety of vision care needs are testament to VTI’s unique approach, where cutting-edge engineering meets relentless drive to make it happen. more.
“For children with progressive myopia, the large number of presbyopes who wish to maintain their natural vision and those in between, VTI continues to advance science to improve the visual health and quality of life of patients in the field. the whole world, ”said Dr Stephen Snowdy, CEO, VTI. “Look for our latest innovations from late 2021 and 2022, including the improved NaturalVue Multifocal and NaturalVue® Multifocal Toric lenses, which will allow practitioners to further extend to patients with astigmatism. VTI has revolutionized practices by delivering innovations that help ECPs redefine what is possible. And, together, the best is yet to come.
About Visioneering Technologies Inc.
Visioneering Technologies Inc. (ASX: VTI) is a healthcare company that makes innovative eye care products available to patients and eye care professionals. Since its inception in 2008, Visioneering has brought together leaders in clinical, marketing, engineering, manufacturing and healthcare regulation to provide new solutions for adults and children in need of healthcare. vision correction.
Based in the United States, Visioneering designs, manufactures, sells and distributes contact lenses around the world. Its flagship product, NaturalVue® Multifocal Contact Lenses, is prescribed in large addressable markets for myopic children and adults over 45, and VTI is expanding its portfolio of technologies to meet a range of other care needs of sight. Since its IPO in 2017, the company has expanded its operations in the United States and recently launched its products in Australia, New Zealand, Singapore, Hong Kong, Canada and Europe.
JAMA Ophthalmol. 2021; 139 (3): 293-300
DeLong, S. Mega Market Trends 2018. Eyecare Business, January 2018: 70.
VTI data on 2015 file. N = 59. Data evaluated after 1 week of wear; vs other traditional ones (lenses with two focal points) studied.
Benoit, Douglas P., Dillehay, Sally M. New clinical evidence over 5 years: NaturalVue Multifocal for Myopia Management. The Myopia Meeting, September 2020.
Nichols J. 2020 contact lenses. Contact lens spectrum. January 2021: 18-25.
Estimate derived from 2020 Nichols J. Contact Lenses data. Contact lens spectrum. January 2021: 18-25 and are used for illustration purposes only.
GfK US FITS Contact Lens Tracker, June 2020.
Data from accounts established after 12 months. Archived VTI data, 2016.
Sully A, Young G, Hunt C. Success factors for new contact lens wearers. Cont Lens Anterior Eye. 2017 Feb; 40: 15-24.